Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCNN1A known ✓ | P37088 | 19/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916781 | 0.99 | SCNN1A (0.56) | SCNN1A | |
| SCHEMBL12120476 | 0.90 | SCNN1A (0.59) | SCNN1A | |
| SCHEMBL9913788 | 0.89 | SCNN1A (0.56) | SCNN1A | |
| SCHEMBL916605 | 0.89 | SCNN1A (0.56) | SCNN1A | |
| SCHEMBL9913787 | 0.89 | SCNN1A (0.62) | SCNN1A | |
| SCHEMBL2333306 | 0.88 | SCNN1A (0.56) | SCNN1A | |
| SCHEMBL12120541 | 0.88 | SCNN1A (0.57) | SCNN1A | |
| SCHEMBL12251645 | 0.88 | SCNN1A (0.53) | SCNN1A | |
| SCHEMBL12251634 | 0.88 | SCNN1A (0.53) | SCNN1A | |
| SCHEMBL2290200 | 0.88 | SCNN1A (0.53) | SCNN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663235-B1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2013-07-24 | — | — | EP | disclosed |
| US-8431579-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2465852-A1 | Capped pyrazinoylguanidine sodium channel blockers | Parion Sciences, Inc. (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20110046158-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-7868010-B2 | N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N-(4-{4-[3-(1H-tetrazol-5-yl)propoxy]phenyl}butyl)guanidine hydrochloride; absorbed less rapidly from mucosal surfaces, less reversible | PARION SCIENCES, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20090018144-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| EP-1663235-A4 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2008-11-12 | — | — | EP | disclosed |
| US-7410968-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20080176863-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080171880-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| EP-1663235-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | Parion Sciences, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1656096-A2 | METHODS OF REDUCING RISK OF INFECTION FROM PATHOGENS | Parion Sciences, Inc. (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20060052395-A1 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-03-09 | — | — | US | disclosed |
| US-20060052394-A1 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-03-09 | — | — | US | disclosed |
| US-20050234072-A1 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC., DURHAM, NC | 2005-10-20 | — | — | US | disclosed |
| US-20050228182-A1 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20050090505-A1 | Methods of reducing risk of infection from pathogens | JOHNSON MICHAEL R (US) | 2005-04-28 | — | — | US | disclosed |
| WO-2005034847-A2 | METHODS OF REDUCING RISK OF INFECTION FROM PATHOGENS | PARION SCIENCES, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050080091-A1 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-04-14 | — | — | US | disclosed |
| WO-2005018644-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046158-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | CACNA1B, CACNA1C, HCN4 | SCNN1A 65/4885 |
| US-20080176863-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | CACNA1B, CACNA1C, HCN4 | SCNN1A 65/4885 |
| US-20060052394-A1 | Capped pyrazinoylguanidine sodium channel blockers | CACNA1B, CACNA1C, HCN4 | SCNN1A 65/4885 |
| US-20050080091-A1 | Capped pyrazinoylguanidine sodium channel blockers | CACNA1B, CACNA1C, HCN4 | SCNN1A 65/4885 |
| US-20050234072-A1 | Capped pyrazinoylguanidine sodium channel blockers | CACNA1B, CACNA1C, HCN4 | SCNN1A 65/4885 |
| US-20050228182-A1 | Capped pyrazinoylguanidine sodium channel blockers | CACNA1B, CACNA1C, HCN4 | SCNN1A 65/4885 |
| US-20050090505-A1 | Methods of reducing risk of infection from pathogens | KCNN3, KCNN1, KCNN2 | SCNN1A 14/4885 |
| US-20060052395-A1 | Capped pyrazinoylguanidine sodium channel blockers | CACNA1B, CACNA1C, HCN4 | SCNN1A 65/4885 |
| US-20080171880-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | CACNA1B, CACNA1C, HCN4 | SCNN1A 65/4885 |
| US-20090018144-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | SCNN1B, SCNN1G, SCNN1A | SCNN1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.